Ace Therapeutics recently launched in vivo efficacy testing services for IBD drug candidates. Ace Therapeutics, a preclinical ...
CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its ...
As of Friday, December 12, Tenaya Therapeutics, Inc.’s TNYA share price has dipped by 32.45%, which has investors questioning ...
Industrialized, small batch, and individual RNA therapeutics become practical with “in-a-box” manufacturing technology.
On December 16, 2025, analyst confidence in Palvella Therapeutics, Inc. (NASDAQ:PVLA) was seen rising, as the company ...
As of Wednesday, December 17, Kyverna Therapeutics, Inc.’s KYTX share price has dipped by 29.30%, which has investors ...
Following encouraging updates from the ongoing Phase 1b PIONEER study evaluating pociredir in sickle cell disease, analyst ...
Kalaris Therapeutics offers differentiated approach to neovascular AMD with its lead candidate TH103. Click here to read my ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback